7 January 2021 - - US-based drug discovery and development service company Crown Bioscience has expanded their NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action and to develop predictive biomarkers for their investigational drug candidates, the company said.

The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures.

This is a significant addition to CrownBio's current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.

The expanded services have been established at the company's Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing, including Illumina's Novaseq 6000 and BGI's MGISEQ-2000 second generation sequencing platform.

PacBio's third generation Sequel sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano's Saphyr Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.

In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis.

Custom NGS services are also available for clients who wish to utilize CrownBio's expertise and large model biobank.

These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel.

The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.

Crown Bioscience, a JSR Life Sciences company, is a drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research.

With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.